Shares of Ligand Pharmaceuticals (LGND +13.9%) are soaring since being removed from a a trading halt earlier this morning. The stock was halted after its partner GlaxoSmithKline (GSK +1%) announced the FDA has approved Promacta for the treatment of thrombocytopenia - a condition in patients with chronic hepatitis C that causes low blood platelet counts - which will allow them to initiate and maintain interferon-based therapy.
From other sites
at CNBC.com (Nov 19, 2012)
at CNBC.com (Sep 7, 2011)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs